Kadmon Holdings (NYSE: KDMN), Initiating Coverage With Buy Rating And First Price Target=$16

KDMN

Kadmon Holdings (KDMN) is a New York-based emerging biotechnology company that is developing novel small molecule product candidates in autoimmune, fibrotic and genetic diseases, and oncology. The company launched it IPO at $12/share in 2016 and the share price is now trading significantly below ...

Kadmon Holdings (KDMN) is a New York-based emerging biotechnology company that is developing novel small molecule product candidates in autoimmune, fibrotic and genetic diseases, and oncology. The company launched it IPO at $12/share in 2016 and the share price is now trading significantly below ...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics